Diagnostic potentials of combined detection of amidolytic activity of hepsin and GSTP1 gene methylation in patients with malignant and other prostate diseases
https://doi.org/10.17650/1726-9776-2008-4-3-50-53
Abstract
We have assessed the implication of analysis of amydolitic activity of hepsin, which is a trans-membrane serine protease of II type, in the detection of prostate cancer diagnosis. According to literature review over-expression of hepsin is characteristic for prostate cancer whereas prostatic cells do not express this protease in normal states and benign tumors of prostate. Our results have demonstrated the value of screening for hepsin activity in the diagnosis of prostatic pathologies which possibly is an adequate substitution for widely used test of prostate specific antigen determination.
About the Authors
Ye. B. Vassileva
I.M. Sechenov Moscow Medical Academy
Russian Federation
Moscow
Russian Federation
Moscow
A. A. Lyashenko
I.M. Sechenov Moscow Medical Academy; Center of Medical biotechnologies
Russian Federation
Moscow
Russian Federation
Moscow
M. V. Savvateeva
Moscow Institute of Medical Ecology
Russian Federation
Moscow
Russian Federation
Moscow
Ye. M. Kuznetsova
Moscow Institute of Medical Ecology
Russian Federation
Moscow
Russian Federation
Moscow
S. Ye. Severin
I.M. Sechenov Moscow Medical Academy; Moscow Institute of Medical Ecology
Russian Federation
Moscow
Russian Federation
Moscow
Ye. S. Severin
I.M. Sechenov Moscow Medical Academy; Research Center for Molecular Diagnostics & Therapy
Russian Federation
Moscow
Russian Federation
Moscow
D. N. Fiyev
I.M. Sechenov Moscow Medical Academy
Russian Federation
Moscow
Russian Federation
Moscow
Yu. G. Aljaev
I.M. Sechenov Moscow Medical Academy
Russian Federation
Moscow
Russian Federation
Moscow
A. Z. Vinarov
I.M. Sechenov Moscow Medical Academy
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Клинические рекомендации. Онкология. Под ред. В.И. Чиссова и С.Л. Дарьяловой. М., ГЕОТАР-Медиа; 2006.
2. Скрининг рака предстательной железы. Методические рекомендации № 543-ПД/623. Сивков А.В. и др.; 2006.
3. Stephan C. et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 2004;171:187—91.
4. Wu Q., Parry G. Hepsin and prostate cancer. Frontiers in Bioscience 2007;12:5052—9.
5. Cairns P. et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001;7:2727—30.
6. Лабинская Т.А. Принципы лабораторной диагностики тромбофилий. Лаборатория 1997;(8).
7. Jerо’nimo C. et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004;10(24):8472—8.
8. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М., МедиаСфера; 2006.
9. Ригельман Р.К. Как избежать врачебных ошибок. Пер. с англ. М., Практика; 1994.
10. Велиев Е.И. Ранняя диагностика локализованных форм рака предстательной железы. Моск здравоохр 2004;(2):20—3.
11. Enokida H. et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005;11:6582—8.
12. Rhodes D.R. et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. JNCI J Natl Cancer Inst 2003;95(9):661—8.
Review
For citations:
Vassileva Ye.B., Lyashenko A.A., Savvateeva M.V., Kuznetsova Ye.M., Severin S.Ye., Severin Ye.S., Fiyev D.N., Aljaev Yu.G., Vinarov A.Z. Diagnostic potentials of combined detection of amidolytic activity of hepsin and GSTP1 gene methylation in patients with malignant and other prostate diseases. Cancer Urology. 2008;4(3):50-53. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-3-50-53
Views:
332
Email this article 